|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Table 3: Mean QOL scores (C30 and CR38) comparing Group 1 and 2 before (T0) and after (T1) neoCRT

|  |  |  |
| --- | --- | --- |
| **EORTC QLQ-C30** | **T0** | **T1** |
| **Group 1 (n=31)** | **Group 2 (n=30)** | **p-value** | **Mean****difference** | **Group 1 (n=31)** | **Group 2 (n=29)** | **p-value** | **Mean****difference** |
| Physical functioning | 85,2 | 88,1 | 0,497 | -2,9 | 87,5 | 87,4 | 0,963 | 0,2 |
| Role functioning | 79,6 | 82,8 | 0,624 | -3,2 | 90,3 | 90,8 | 0,915 | -0,5 |
| Cognitive functioning | 78,5 | 80,6 | 0,722 | -2,1 | 85,5 | 86,2 | 0,876 | -0,7 |
| Emotional functioning | 68,2 | 64,3 | 0,585 | 3,9 | 73,4 | 69,8 | 0,593 | 3,6 |
| Social functioning | 79,0 | 76,1 | 0,665 | 2,9 | 87,1 | 86,7 | 0,942 | 0,4 |
| Fatigue | 22,7 | 18,5 | 0,506 | 4,2 | 14,7 | 9,6 | 0,180 | 5,1 |
| Pain | 32,3 | 26,7 | 0,397 | 5,6 | 19,4 | 10,9 | 0,172 | 8,4 |
| Dyspnea | 8,9 | 6,7 | 0,715 | 2,2 | 7,5 | 3,4 | 0,304 | 4,1 |
| Insomnia | 30,1 | 17,8 | 0,184 | 12,3 | 13,3 | 19,5 | 0,360 | -6,2 |
| Appetite Loss | 15,6 | 12,2 | 0,595 | 3,3 | 9,7 | 3,4 | 0,212 | 6,2 |
| Nausea | 2,7 | 6,1 | 0,243 | -3,4 | 0,5 | 0,0 | 0,338 | 0,5 |
| Constipation | 39,8 | 23,3 | 0,085 | 16,4 | 16,1 | 14,9 | 0,875 | 1,2 |
| Diarrhea | 24,4 | 20,0 | 0,598 | 4,5 | 3,2 | 8,0 | 0,138 | -4,8 |
| Financial difficulties | 38,7 | 34,4 | 0,676 | 4,3 | 23,7 | 25,3 | 0,857 | -1,6 |
| Global Health Status | 73,7 | 63,3 | **0,033** | 10,3 | 79,6 | 76,2 | 0,469 | 3,4 |
| **C30SumScale** | 77,9 | 81,6 | 0,316 | -3,6 | 87,6 | 88,4 | 0,744 | -0,8 |
| **EORTC CR38** | **T0** | **T1** |
| **Group 1 (n=31)** | **Group 2 (n=30)** | **p-value** | **Mean****difference** | **Group 1 (n=31)** | **Group 2 (n=29)** | **p-value** | **Mean****difference** |
| Miccional problems | 36,9 | 37,0 | 0,980 | -0,1 | 37,616 | 40,990 | 0,525 | -3,4 |
| Gastrointestinal problems | 23,9 | 22,4 | 0,763 | 1,4 | 13,116 | 20,000 | 0,096 | -6,9 |
| Weight Loss | 37,8 | 36,7 | 0,925 | 1,1 | 11,823 | 19,541 | 0,274 | -7,7 |
| Chemotherapy side effects | 16,8 | 10,9 | 0,247 | 5,9 | 13,968 | 9,190 | 0,219 | 4,8 |
| Defecation problems | 36,4 | 36,7 | 0,947 | -0,3 | 15,996 | 22,275 | 0,168 | -6,3 |
| Male sexual problems | 14,4 | 22,2 | 0,464 | -7,8 | 8,340 | 30,213 | 0,104 | -21,9 |
| Female sexual problems | 30,0 | 10,0 | 0,242 | 20,0 | 50,000 | 27,767 | 0,467 | 22,2 |
| Stoma related problems | 23,8 | 14,3 | 0,742 | 9,5 | 4,455 | 0,166 | 0,128 | 4,3 |
| Body image | 14,3 | 15,9 | 0,790 | -1,6 | 12,545 | 10,341 | 0,701 | 2,2 |
| Future perspectives | 60,2 | 67,8 | 0,526 | -7,6 | 51,610 | 64,362 | 0,205 | -12,8 |
| Sexual functioning | 38,5 | 31,6 | 0,392 | 6,9 | 27,789 | 36,307 | 0,281 | -8,5 |
| Sexual satisfaction | 51,7 | 60,0 | 0,508 | -8,3 | 66,668 | 60,605 | 0,621 | 6,1 |

QOL: Quality of Life; neoCRT: neoadjuvant chemoradiotherapy; |